We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Bayer Aktiengesellschaft (PK) | USOTC:BAYRY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.0399 | -0.52% | 7.6801 | 7.67 | 7.73 | 7.75 | 7.63 | 7.66 | 1,635,781 | 21:00:25 |
From May 2021 to May 2024
By Colin Kellaher
Bayer AG on Monday said it has filed for U.S. and European expanded approval of its cancer drug Aliqopa in combination with rituximab, a drug used to treat certain types of cancer and rheumatoid arthritis.
The Leverkusen, Germany, chemical and pharmaceutical company said it is seeking U.S. Food and Drug Administration approval of the combination in relapsed indolent B-cell non-Hodgkin's lymphoma.
The company said it also has filed for European Medicines Agency approval for the treatment of relapsed marginal zone lymphoma, a subtype of indolent B-cell non-Hodgkin's lymphoma.
Bayer in April said a Phase III study showed a significant progression-free survival benefit for the combination in patients with relapsed indolent non-Hodgkin's lymphoma.
The FDA in 2017 approved Aliqopa for adults with relapsed follicular lymphoma who have received at least two prior systemic therapies.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 21, 2021 11:26 ET (15:26 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Bayer Aktiengesellschaft (PK) Chart |
1 Month Bayer Aktiengesellschaft (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
